Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 5/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886722 | 0.91 | RXRA (0.46) | ALDH1A1CETPADAMTS4RXRASCN9A | |
| SCHEMBL5887156 | 0.90 | ADAMTS4 (0.43) | ALDH1A1CETPADAMTS4RXRASCN9A | |
| SCHEMBL5886729 | 0.87 | ALDH1A1 (0.37) | ALDH1A1CETPADAMTS4RXRASCN9A | |
| SCHEMBL5887057 | 0.86 | DRD2 (0.41) | ADAMTS4SCN9AMAPTHDAC6NPC1 | |
| SCHEMBL5887343 | 0.84 | PRMT5 (0.43) | ALDH1A1ADAMTS4MAPTKDM4EHDAC6 | |
| SCHEMBL5886750 | 0.84 | ADAMTS4 (0.45) | ALDH1A1ADAMTS4MAPT | |
| SCHEMBL5887084 | 0.84 | ALDH1A1 (0.42) | ALDH1A1RXRAMAPTPKMNPC1 | |
| SCHEMBL5886716 | 0.84 | SMN1; SMN2 (0.41) | ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL5887024 | 0.83 | MAPT (0.44) | ALDH1A1ADAMTS4MAPTKDM4EHDAC6 | |
| SCHEMBL5887054 | 0.82 | HDAC6 (0.46) | ALDH1A1ADAMTS4MAPTHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | ALDH1A1 1860/4885CETP 3984/4885ADAMTS4 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.